ATLANTA, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from its Phase 3 (FAME™) clinical trials for Iluvien® will be presented this month at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago. Iluvien is Alimera's investigational intravitreal insert being studied for diabetic macular edema (DME). The presentation, by Baruch Kuppermann, M.D., Ph.D, professor and chief of the Retina Service at University of California, Irvine, is slated for 4:19 p.m., Saturday, October 16, during the Retina 2010 subspecialty day program.
Alimera Sciences' FAME(TM) Study Data On Iluvien(R) To Be Presented At AAO 2010 Annual Meeting
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.